Patent CA-2025599-C (CA)
Title: Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
Inventor: MATSUO MASAAKI
IPC: C07D403/04
Filed: 1990-09-18
Granted: 2001-11-20
Abstract: There are described compounds of the formula: (see formula I) wherein R1 is aryl which may be substituted with substituent(s) selected from the group consisting of lower alkyl, halogen, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, hydroxy, lower alkylsulfonyloxy, nitro, amino, lower alkylamino, acylamino and lower alkyl(acyl)-amino; or a heterocyclic group; R2 is hydrogen; methyl substituted with amino, lower aklylamino, halogen or acyloxy; acyl; acylamino; cyano; halogen; lower alkylthio; lower alkylsufinyl; or a hetero-cyclic group; and R3 is aryl substituted with lower alkyl, lower alkylthio, lower alkylsulfinyl, halogen, amino, lower alkylamino, acylamino, lower alkyl(acyl)amino, lower alkoxy, cyano, hydroxy or acyl; or a heterocyclic group which may be substituted with lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl provided that when R2 is carboxy, esterified carboxy or tri(halo)methyl, then R3 is aryl substituted with lower alkylthio, lower alkylsulfinyl, amino, lower alkylamino, acylamino, lower alkyl(acyl)amino, hydroxy or acyl; or a heterocyclic group substituted with lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl; or R1 is aryl substituted with substituent(s) selected from the group consisting of lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, hydroxy, lower alkylsulfonyloxy, nitro, amino, lower alkylamino, acylamino and lower alkyl(acyl)amino; or a heterocyclic group; and a pharmaceutically acceptable salts thereof.      These compounds are useful for the treatment and/or prevention of inflammation and pain in joint and muscle [e.g. rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, etc.], inflammatory skin condition [e.g. sunburn, eczema, etc.] inflammatory eye condition [e.g. conjunctivitis, etc.], lung disorder in which inflammation is involved [e.g. asthma, bronchitis, pigeon fancier's disease, farmer's lung, etc.], condition of the gastro-intestinal tract associated with inflammation [e.g. aphthous ulcer, Chrohn's disease, atropic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, irritable bowel syndrome, etc.], gingivitis, inflammation, pain and tumescence after operation or injury, pyresis, pain and other conditions associated with inflammation, particularly those in which lipoxygenase and cyclooxygenase products are a factor, systemic lupus erythematosus, scleroderma, polymyositis, periarteritis nodosa, rheumatic fever, Sjögren's syndrome, Behcet disease, thyroiditis, type I diabetes, nephrotic syndrome, aplastic anemia, myasthenia gravis, uveitis contact dermatitis, psoriasis, Kawasaki disease, sarcoidosis, Hodgkin's disease, and the like. Additionally, the compounds are expected to be useful as thera-peutical and/or preventive agents for cardiovascular or cerebrovascular diseases, the diseases caused by hyperglycemia and hyperlipemia. Also disclosed are the preparation of these compounds, pharmaceutical preparations containing them and therapeutic treat-ments involving the use of these compounds.